BioNTech SE
BNTX
$89.27
-$0.04-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -16.73% | 29.76% | 113.67% | -5.54% | -20.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.73% | 29.76% | 113.67% | -5.54% | -20.33% |
| Cost of Revenue | 35.80% | -11.85% | 34.71% | 37.45% | 34.62% |
| Gross Profit | -30.24% | 36.74% | 182.20% | -25.32% | -27.90% |
| SG&A Expenses | 80.14% | 4.93% | -21.18% | -11.83% | -8.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 355.39% | 113.27% | -110.21% | -502.15% | 110.26% |
| Total Operating Expenses | 28.10% | 34.84% | -32.56% | -4.96% | 115.70% |
| Operating Income | -308.49% | -267.91% | 52.12% | 4.74% | -84.39% |
| Income Before Tax | -182.45% | -83.45% | 47.30% | -30.13% | -55.03% |
| Income Tax Expenses | 103.22% | 244.13% | -948.81% | -71.82% | -79.89% |
| Earnings from Continuing Operations | -228.35% | -115.41% | 49.54% | -27.92% | -43.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -228.35% | -115.41% | 49.54% | -27.92% | -43.89% |
| EBIT | -308.49% | -267.91% | 52.12% | 4.74% | -84.39% |
| EBITDA | -204.75% | 48.52% | 55.40% | 5.81% | -73.48% |
| EPS Basic | -226.29% | -115.56% | 49.79% | -28.02% | -44.02% |
| Normalized Basic EPS | -167.07% | -78.14% | 49.25% | -31.04% | -51.71% |
| EPS Diluted | -226.29% | -115.76% | 49.79% | -28.02% | -43.63% |
| Normalized Diluted EPS | -167.07% | -77.87% | 49.25% | -31.04% | -51.45% |
| Average Basic Shares Outstanding | 1.63% | -1.00% | 0.50% | -0.08% | 0.23% |
| Average Diluted Shares Outstanding | 1.63% | -2.21% | 0.50% | -0.08% | -0.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |